Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13847
Abstract: It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However,… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13884
Abstract: Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is a more common disease than previously thought. Awareness of ATTRwt CM and its diagnosis has been challenged by its unspecific and widely distributed clinical manifestations and traditionally invasive… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13909
Abstract: To clarify the usefulness of left atrial (LA) function and left ventricular (LV) function obtained by two‐dimensional (2D) speckle tracking echocardiography to diagnose concomitant transthyretin amyloid cardiomyopathy (ATTR‐CM) in patients with aortic stenosis (AS). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13961
Abstract: Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14188
Abstract: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14350
Abstract: Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health‐related quality of life (HRQoL) in ATTR CM patients. read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "American heart journal"
DOI: 10.1016/j.ahj.2021.02.016
Abstract: OBJECTIVE Amyloid cardiomyopathy (ACM) is a progressive and life-threatening disease caused by abnormal protein deposits within cardiac tissue. The most common forms of ACM are caused by immunoglobulin derived light chains (AL) and transthyretin (TTR).… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Cardiac Failure"
DOI: 10.1016/j.cardfail.2019.07.512
Abstract: Objective Amyloid cardiomyopathy (ACM) is a progressive and life-threatening disease characterized by abnormal proteinaceous deposits within the cardiac extracellular space. The most common forms of ACM are caused by immunoglobulin derived light chains (AL) and… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31447-9
Abstract: Transthyretin amyloid cardiomyopathy (ATTR-CM) may be more common than previously thought and is often underdiagnosed. We sought to evaluate traditionally accepted “red flag” clinical features with novel methods. We identified a random sample of 46… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Case Reports in Medicine"
DOI: 10.1155/2018/1864962
Abstract: Infiltrative cardiomyopathies include a variety of disorders that lead to myocardial thickening resulting in a constellation of clinical manifestations and eventually heart failure that could be the first clue to reach the diagnosis. Among the… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Cardiology"
DOI: 10.1159/000455089
Abstract: Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR). However, the efficacy of tafamidis against ATTR-related cardiac amyloidosis remains… read more here.